Microglia: A Potential Therapeutic Target for Sepsis-Associated Encephalopathy and Sepsis-Associated Chronic Pain.
chronic pain
microglia
neuroinflammation
sepsis
sepsis-associated encephalopathy
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2020
2020
Historique:
received:
30
08
2020
accepted:
23
10
2020
entrez:
17
12
2020
pubmed:
18
12
2020
medline:
18
12
2020
Statut:
epublish
Résumé
Neurological dysfunction, one of the severe manifestations of sepsis in patients, is closely related to increased mortality and long-term complications in intensive care units, including sepsis-associated encephalopathy (SAE) and chronic pain. The underlying mechanisms of these sepsis-induced neurological dysfunctions are elusive. However, it has been well established that microglia, the dominant resident immune cell in the central nervous system, play essential roles in the initiation and development of SAE and chronic pain. Microglia can be activated by inflammatory mediators, adjacent cells and neurotransmitters in the acute phase of sepsis and then induce neuronal dysfunction in the brain. With the spotlight focused on the relationship between microglia and sepsis, a deeper understanding of microglia in SAE and chronic pain can be achieved. More importantly, clarifying the mechanisms of sepsis-associated signaling pathways in microglia would shed new light on treatment strategies for SAE and chronic pain.
Identifiants
pubmed: 33329005
doi: 10.3389/fphar.2020.600421
pii: 600421
pmc: PMC7729164
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
600421Informations de copyright
Copyright © 2020 Li, Yin, Fan, Su, Chen, Ma, Zhong, Hou, Fang and Zhang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nat Rev Neurosci. 2009 Jan;10(1):23-36
pubmed: 19096368
Mol Imaging Biol. 2018 Dec;20(6):952-962
pubmed: 29736562
Lancet Neurol. 2014 Jun;13(6):534-6
pubmed: 24849853
JAMA. 2010 Oct 27;304(16):1787-94
pubmed: 20978258
Comp Med. 2019 Dec 1;69(6):546-554
pubmed: 31213216
J Neurochem. 2016 Jan;136 Suppl 1:10-7
pubmed: 25693054
J Neuroinflammation. 2015 Jun 06;12:114
pubmed: 26048578
Lab Invest. 2007 Dec;87(12):1186-94
pubmed: 17922019
Shock. 2013 May;39 Suppl 1:10-6
pubmed: 23481496
Neurol India. 2018 Mar-Apr;66(2):352-361
pubmed: 29547154
Crit Care. 2010;14(5):199
pubmed: 21067627
Nat Rev Neurosci. 2018 Mar;19(3):138-152
pubmed: 29416128
Intensive Care Med Exp. 2015 Dec;3(1):30
pubmed: 26515197
Nat Neurosci. 2015 Aug;18(8):1081-3
pubmed: 26120961
Can J Physiol Pharmacol. 2018 Mar;96(3):241-248
pubmed: 28817786
Int Rev Psychiatry. 2009 Feb;21(1):30-42
pubmed: 19219711
J Neuroimmunol. 2017 Feb 15;303:90-98
pubmed: 28087076
Pain. 2018 Oct;159(10):1908-1915
pubmed: 29889119
Nat Rev Neurosci. 2015 Dec;16(12):705-18
pubmed: 26585799
Pain. 2013 Dec;154 Suppl 1:S10-28
pubmed: 23792284
Annu Rev Physiol. 2017 Feb 10;79:619-643
pubmed: 27959620
Neuron. 2018 Dec 19;100(6):1292-1311
pubmed: 30571942
N Engl J Med. 2019 Jun 27;380(26):2506-2517
pubmed: 31112380
Mediators Inflamm. 2016;2016:1045657
pubmed: 26924896
J Cell Biochem. 2019 Jan 22;:
pubmed: 30672013
J Neurochem. 2018 Jun;145(6):474-488
pubmed: 29500815
Anesthesiology. 2018 Aug;129(2):343-366
pubmed: 29462012
Intensive Care Med. 2011 Apr;37(4):711-8
pubmed: 21350907
Neuropharmacology. 2009;56 Suppl 1:244-53
pubmed: 18722389
CNS Neurol Disord Drug Targets. 2013 Sep;12(6):720-5
pubmed: 24047519
Mediators Inflamm. 2019 Oct 7;2019:8461725
pubmed: 31686986
CMAJ. 2018 Sep 10;190(36):E1083
pubmed: 30201616
Rheumatol Int. 2017 Jan;37(1):29-42
pubmed: 27107994
Nat Rev Neurosci. 2020 Mar;21(3):139-152
pubmed: 32042145
J Neurosci. 2008 May 14;28(20):5189-94
pubmed: 18480275
Nat Rev Immunol. 2017 Jul;17(7):407-420
pubmed: 28436424
Crit Care. 2013 May 29;17(3):R101
pubmed: 23718685
Brain Behav Immun. 2015 Jan;43:54-9
pubmed: 25019583
J Neuroimmunol. 2015 Aug 15;285:31-40
pubmed: 26198916
Front Neurosci. 2019 Apr 24;13:358
pubmed: 31068775
Crit Care. 2017 Mar 21;21(1):65
pubmed: 28320461
Front Neurol. 2020 Feb 14;11:87
pubmed: 32117037
Pain Med. 2009 May-Jun;10(4):663-72
pubmed: 19453963
Ann Intensive Care. 2012 Aug 16;2(1):36
pubmed: 22898192
Immun Ageing. 2019 Jul 30;16:18
pubmed: 31384283
Cell Res. 2015 Jun;25(6):674-90
pubmed: 25998681
Braz J Psychiatry. 2014 Sep;36(3):251-8
pubmed: 24918523
Crit Care. 2012 Oct 04;16(5):R181
pubmed: 23036135
Lancet. 2010 Feb 27;375(9716):773-5
pubmed: 20189029
Brain. 2015 Mar;138(Pt 3):604-15
pubmed: 25582579
J Pain. 2010 Oct;11(10):1004-14
pubmed: 20434956
Nature. 2013 Sep 5;501(7465):52-7
pubmed: 23965627
Curr Infect Dis Rep. 2016 Nov;18(11):37
pubmed: 27709504
Lancet. 2010 Nov 27;376(9755):1829-37
pubmed: 21056464
Science. 2016 Nov 4;354(6312):572-577
pubmed: 27811267
Front Immunol. 2017 Jan 19;8:17
pubmed: 28154566
J Dent Res. 2011 Jun;90(6):759-64
pubmed: 21393555
Brain Behav Immun. 2010 May;24(4):641-51
pubmed: 20138983
J Neuroinflammation. 2014 Feb 27;11:36
pubmed: 24571599
Crit Care Med. 2016 Jun;44(6):1129-37
pubmed: 26958751
Br J Pharmacol. 2016 Mar;173(5):856-69
pubmed: 26603732
Phytomedicine. 2016 Dec 1;23(13):1629-1637
pubmed: 27823627
Neurosci Lett. 2018 Jan 1;662:361-367
pubmed: 29102784
Pain Physician. 2017 May;20(4):293-305
pubmed: 28535552
J Neuroinflammation. 2007 Jan 15;4:4
pubmed: 17224051
Sci Rep. 2017 Mar 23;7(1):375
pubmed: 28336953
Lancet Neurol. 2014 Jun;13(6):630-6
pubmed: 24849863